European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This overview presents the updated European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur Urol

Title: European urology

Publisher: Elsevier BV

ISSN (Electronic): 1873-7560

ISSN (Print): 0302-2838

Publication date (Electronic): Nov 2019

Volume: 76

Issue: 5

Affiliations

[1 ] Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: Marek.Babjuk@fnmotol.cz.

[2 ] Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.

[3 ] Department of Pathology, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, UPMC Paris VI, Paris, France.

[4 ] Division of Urology, Molinette Hospital, University of Studies of Torino, Torino, Italy.

[5 ] Department of Urology, Royal Surrey County Hospital, Guildford, Surrey, UK.

[6 ] Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.

[7 ] Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

[8 ] Urology Department, Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.

[9 ] Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.

[10 ] European Association of Urology Guidelines Office, Brussels, Belgium.

[11 ] Department of Urology, Medical University of Graz, Graz, Austria.

[12 ] Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.

[13 ] Department of Urology, Royal Free London NHS Foundation Trust, London, UK.

[14 ] Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.

[15 ] Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.

[16 ] Department of Urology, University of Rennes, Rennes, France.

Article

Publisher Item ID: S0302-2838(19)30660-8

DOI: 10.1016/j.eururo.2019.08.016

PubMed ID: 31443960

SO-VID: a41b2fe8-7f6a-4567-81ce-0d5135659620

History

Keywords: Bacillus Calmette-Guérin,Bacillus Calmette-Guérin unresponsive,Bladder cancer,Cystoscopy,Diagnosis,European association of urology,Follow-up,Guidelines,Intravesical chemotherapy,Prognosis,Radical cystectomy,Transurethral resection,Urothelial carcinoma

Data availability:

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Read this article at

Abstract

Related collections

Karger: Oncology

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 472